Thus, suppression of TG biosynthesis by selective inhibition of DGAT2 improves steatohepatitis and insulin sensitivity, but at the same time exacerbates liver damage in a methionine and choline deficient (MCD) mouse model of NASH 6. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatohepatitis.